40
Participants
Start Date
July 31, 2012
Primary Completion Date
July 31, 2025
Study Completion Date
December 31, 2034
alemtuzumab
Conditioning: alemtuzumab 0.2 mg/kg/dose IV/SC x 5 doses
Fludarabine
fludarabine 30 mg/m2/dose IV x 6 doses
Cyclosporins
Mycophenolate mofetil
Tacrolimus
Children's Hospital of Philadelphia, Philadelphia
Duke University Medical Center, Pediatric BMT, Durham
Cincinnati Children's Hospital Medical Center, Cincinnati
University of Wisconsin Hospital and Clinics, Madison
Mayo Clinic, Rochester
University of Chicago, Chicago
Children's Mercy Hospital Kansas City, Kansas City
Baylor College of Medicine, Houston
Children's Hospital Los Angeles, Los Angeles
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle
Massachusetts General Hospital, Boston
Boston Children's Hospital (pediatric patients), Boston
Dana-Farber Cancer Institute (adult patients), Boston
Hackensack University Medical Center, Hackensack
Oslo University Hospital, Oslo
Karolinska University Hospital, Stockholm
Collaborators (2)
Dana-Farber Cancer Institute
OTHER
Children's Hospital Medical Center, Cincinnati
OTHER
Children's Hospital Los Angeles
OTHER
Fred Hutch/University of Washington/Seattle Children's Cancer Consortium
UNKNOWN
Baylor College of Medicine
OTHER
Children's Hospital of Philadelphia
OTHER
University of Wisconsin, Madison
OTHER
Karolinska University Hospital
OTHER
Hackensack Meridian Health
OTHER
Duke University
OTHER
Oslo University Hospital
OTHER
Children's Mercy Hospital Kansas City
OTHER
Mayo Clinic
OTHER
University of Chicago
OTHER
Massachusetts General Hospital
OTHER
Boston Children's Hospital
OTHER